Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management.
18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain.
Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be a marker of disease progression.
Dementia is an umbrella term
Understanding What to do
Come Share With Us
African American Support Group meeting the 2nd Wednesday of every month from 6:00-800 pm at West Charlotte Recreation Center (Address: 2401 Kendall Dr, Charlotte, NC 28216)
Person- first perspective
Make choice available
Dementia care qualifications
Are you interested in highlighting your Dementia/Alzheimer’s service?